Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Nabriva Therapeutics
Nabriva Therapeutics
(NBRV)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Xenleta
Lefamulin
2020-07-27
2028-2031
Community-acquired infections
,
Bacterial pneumonia
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Lefamulin
healthy volunteers/patients
,
fibrosis
,
cystic fibrosis
,
infections
,
bacterial infections
,
mycoplasma infections
,
pleuropneumonia
,
mycoplasma genitalium
,
pneumonia
,
community-acquired pneumonia
Bevifimod
neoplasms
,
small cell lung carcinoma
,
neuroendocrine tumors
,
carcinoid tumor
Lactams
healthy volunteers/patients
Trinessa
cardiovascular abnormalities
Fluoroquinolone
patient preference
,
postoperative pain
,
keratoconus
Isoxaflutole
breast neoplasms
,
triple negative breast neoplasms
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use